Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.

2.

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

Neukirchen-Strapatsas J, Tuechler H, Porta MD, Fenaux P, Guerci A, Haas R, Rossi M, Sapena R, Sperr WR, Strupp C, Stamatoullas A, Valent P, Germing U, Bennett JM.

Leuk Res. 2019 Feb;77:8-13. doi: 10.1016/j.leukres.2018.12.012. Epub 2018 Dec 28.

PMID:
30605856
3.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P.

Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13.

PMID:
30004110
4.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
5.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. No abstract available.

PMID:
26773632
6.

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S.

Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. No abstract available.

7.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi B, Delaunay J, Gourin MP, Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljassem L, Raffoux E, Itzykson R, Adès L, Dreyfus F, Fenaux P.

Leukemia. 2013 Jun;27(6):1283-90. doi: 10.1038/leu.2013.16. Epub 2013 Jan 16.

PMID:
23370672
8.

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P.

Ann Hematol. 2013 May;92(5):621-31. doi: 10.1007/s00277-013-1686-4. Epub 2013 Jan 29. Erratum in: Ann Hematol. 2013 May;92(5):633. Lambert, Christine [corrected to Lamberto, C].

PMID:
23358617
9.

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F.

Leuk Res. 2011 Nov;35(11):1530-3. doi: 10.1016/j.leukres.2011.07.007. Epub 2011 Jul 30.

PMID:
21803419
10.

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, Bordessoule D, Stamatoullas A, Castaigne S, Terré C, Eclache V, Fenaux P, Adès L.

Leuk Res. 2011 Jul;35(7):863-7. doi: 10.1016/j.leukres.2011.02.008. Epub 2011 Mar 10.

PMID:
21396711
11.

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F.

Leuk Res. 2010 Nov;34(11):1430-6. doi: 10.1016/j.leukres.2010.05.030. Epub 2010 Jun 26.

PMID:
20580086
12.

Nodular osteochondrogenic activity in soft tissue surrounding osteoma in neurogenic para osteo-arthropathy: morphological and immunohistochemical study.

Youssefian T, Sapena R, Carlier R, Bos C, Denormandie A, Denys P, Cormier A, Bandelier M.

BMC Musculoskelet Disord. 2004 Nov 25;5:46.

13.

Evidence for sigma-1-like receptors in isolated rat liver mitochondrial membranes.

Klouz A, Sapena R, Liu J, Maurice T, Tillement JP, Papadopoulos V, Morin D.

Br J Pharmacol. 2002 Apr;135(7):1607-15.

14.

Attenuation of liver normothermic ischemia--reperfusion injury by preservation of mitochondrial functions with S-15176, a potent trimetazidine derivative.

Elimadi A, Sapena R, Settaf A, Le Louet H, Tillement J, Morin D.

Biochem Pharmacol. 2001 Aug 15;62(4):509-16.

PMID:
11448461
15.

S-15176 reduces the hepatic injury in rats subjected to experimental ischemia and reperfusion.

Settaf A, Zahidy M, Elimadi A, Sapena R, Alsamad IA, Tillement J, Morin D.

Eur J Pharmacol. 2000 Oct 13;406(2):281-92.

PMID:
11020492
16.
18.

Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function.

Elimadi A, Settaf A, Morin D, Sapena R, Lamchouri F, Cherrah Y, Tillement JP.

J Pharmacol Exp Ther. 1998 Jul;286(1):23-8.

PMID:
9655837
19.

Dose-related inversion of cinnarizine and flunarizine effects on mitochondrial permeability transition.

Elimadi A, Bouillot L, Sapena R, Tillement JP, Morin D.

Eur J Pharmacol. 1998 May 1;348(1):115-21.

PMID:
9650838
20.

Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore.

Morin D, Elimadi A, Sapena R, Crevat A, Carrupt PA, Testa B, Tillement JP.

Br J Pharmacol. 1998 Apr;123(7):1385-94.

21.
22.

Comparison of the effects of cyclosporine A and trimetazidine on Ca(2+)-dependent mitochondrial swelling.

Elimadi A, Morin D, Sapena R, Chauvet-Monges AM, Crevat A, Tillement JP.

Fundam Clin Pharmacol. 1997;11(5):440-7.

PMID:
9342597
23.

Characterization of beta-adrenergic receptors of freshly isolated astrocytes and neurons from rat brain.

Morin D, Sapena R, Zini R, Onteniente B, Tillement JP.

Life Sci. 1997;60(4-5):315-24.

PMID:
9010487
24.

Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes.

Sapena R, Morin D, Zini R, Morin C, Tillement JP.

Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62.

PMID:
8741184
25.

Isoproterenol interacts differently with beta-adrenoceptors in astrocytes and neurons isolated from the adult rat brain.

Sapena R, Morin D, Zini R, Tillement JP.

Biochem Pharmacol. 1994 Jan 20;47(2):175-8.

PMID:
8304961
26.
27.

Evaluation of central adrenergic receptor signal transmissions after an antidepressant administration to the rat.

Sapena R, Morin D, Zini R, Tillement JP.

Biochem Pharmacol. 1992 Sep 25;44(6):1067-72.

PMID:
1329757
28.

Serotonin enhances the beta-adrenergic response in rat brain cortical slices.

Morin D, Sapena R, Zini R, Tillement JP.

Eur J Pharmacol. 1992 Mar 12;225(3):273-4.

PMID:
1325368
29.

Labelling of rat brain beta-adrenoceptors: (3H)CGP-12177 or (125I)iodocyanopindolol?

Morin D, Zini R, Urien S, Sapena R, Tillement JP.

J Recept Res. 1992;12(3):369-87.

PMID:
1354747
30.

A method to measure simultaneously cyclic AMP and inositol phosphate accumulation in rat brain slices.

Morin D, Zini R, Querol-Ferrer V, Sapena R, Tillement JP.

J Neurochem. 1991 Apr;56(4):1114-20.

PMID:
1705955

Supplemental Content

Loading ...
Support Center